1. Global Portfolio of Antimalarial Medicines
Translational
Product development
Access
Human volunteers
Patient exploratory
Patient confirmatory
Regulatory review
Preclinical
Approved/ERP
SAR121
Sanofi
P218
Janssen
AQ13
Immtech
Artefenomel/
Ferroquine
Sanofi
Dihydroartemisinin- piperaquine dispersible
Alfasigma
Arterolane-
piperaquine
Sun Pharma
Artemether-
lumefantrine
Various Manufacturers
Artesunate-
amodiaquine
Various Manufacturers 3 6 1
GSK701
GSK
SJ733
Kentucky/Eisai
Sevuparin
Modus Therapeutics
Ganaplacide/
Lumefantrine
Novartis
Co-trimoxazole
ITM Antwerp
Artesunate-
mefloquine
Cipla
Artemether-
lumefantrine
Dispersible
Various Manufacturers
NPC1161B
Mississippi
ACT
Actelion
MMV048
MMV
Cipargamin
Novartis
Artemisinin-
naphthoquine
Kunming Pharma Co 2
Sulfadoxine-
pyrimethamine+
Amodiaquine dispersible
Various Manufacturers
Artesunate
for Injection
Various Manufacturers
MK4815
Merck
CDRI 9778
Ipca
Rosiglitazone adjunct therapy Manhica, Toronto, Barcelona
DSM265
Takeda
Artemether sub-lingual spray
MRC/Suda 7 3
Rectal artesunate
Various Manufacturers
Dihydroartemisinin- piperaquine
Various Manufacturers
SC83288
Heidelberg University
M5717
Merck KGaA
Imatinib
HuLow, Purdue, Turin, Sassari and Hue
Fosmidomycin Piperaquine
DMG Deutsche Malaria GmbH
Artemisinin- piperaquine
Artepharm
8, 9 4
Tafenoquine
GSK 10
Isoxazolines
Calibr TropIQ
DM1157
DesignMedix
Methylene Blue/ amodiaquine
Heidelberg
Tafenoquine paediatric GSK
Pyronaridine-
Artesunate Shin Poong
Artesunate-
amodiaquine
Sanofi 5
Tafenoquine
60P/US Army 11
MMV370
MMV371
Janssen
MMV253
Zydus Cadila
Pyronaridine-
artesunate granules
Shin Poong 5
Footnotes: Included in MMV portfolio after product approval and/or development. DNDi and partners completed development and registration of ASMQ and ASAQ. │ Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing. │ WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers. │ Paediatric formulation.

2. Footnotes: Global Portfolio
Target Product Profiles and Target Candidate Profiles
MMV has defined Target Product Profiles and Target Candidate Profiles for medicines to support the eradication campaign.
Burrows JN et al., New developments in anti‑malarial target candidate and product profiles et al. Malar J (2017) 16:26 updates the previous profiles in Burrows J et al.; Malaria Journal :187
Target Product Profiles
indicated by bars at the bottom of each compound box
Target Candidate Profiles
activities for each individual molecule, indicated by symbols added to compounds in the translational or product development portfolio
Burrows Burrows
et al., 2013 et al., 2017
Asexual blood stages (TCP-1,2) TCP-1
Relapse prevention (TCP-3a) TCP-3
Transmission reduction (TCP-3b) TCP-5,6
Prophylaxis (TCP- 4) TCP-4
3-day cure, artemisinin-based combination therapies
Uncomplicated malaria treatments aiming at a new single-exposure radical cure (SERC) TPP-1
Severe malaria treatment / pre-referral intervention
Intermittent/seasonal malaria chemoprevention
Products targeting prevention of relapse for P. vivax
Single-exposure chemoprotection (SEC) TPP-2
Footnote for Generic names on Global Portfolio
1. First approval: Novartis (Brand name: Coartem®). Generics by Ajanta, Cipla, Ipca, Strides Pharma, Macleods, Mylan  
First approval: Novartis (Brand name: Coartem® Dispersible). Generics by Ajanta; Cipla; Strides Pharma; Ipca
Brand names: Artesun® (Fosun Pharma), Larinate® 60mg (Ipca)
First approval: Alfasigma (Brand name: Eurartesim®). Generic by Fosun (ERP only)
Brand name: Pyramax® tablets and granules
First approval fixed-dose combination: Sanofi/DNDi (Brand name: ASAQ Winthrop). Generics by Ajanta, Cipla, Fosun, Ipca, Strides Pharma
Brand name: SPAQ-COTM
100mg Artesunate Rectocaps
ArtecapTM
Brand names: Kozenis/Krintafel (Trademarks owned or licensed by GSK)
Brand names: ARAKODATM/KODATEF (60 Degrees Pharmaceuticals)
Additional Symbols on Global Portfolio
Brought into portfolio after approval; collaborations with DNDi
No progress report in the last two years
Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing.
Paediatric formulation
WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers.
Approved in several countries but not approved by WHO pre-qualification nor regulatory bodies who are ICH members or observers
In partnership with MMV